Asia Pacific Coagulation Analyzers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis– by Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time

Asia Pacific Coagulation Analyzers Market Forecast to 2028 – COVID-19 Impact and Regional Analysis– by Product (Clinical Laboratory Analyzers and Point-of-care Testing Analyzers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, Anti-Factor XA Tests, Heparin and Protamine Dose Response Tests for ACT, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, Point-of-Care Testing, and Others) 

The Asia Pacific coagulation analyzers market is expected to grow from US$ 591.16 million in 2022 to US$ 891.91 million by 2028. It is estimated to grow at a CAGR of 7.1% from 2022 to 2028.

Rising Incidence of Cardiovascular Diseases is Driving the Asia Pacific Coagulation Analyzers Market

In recent years, changing lifestyle habits and growing geriatric population are increasing the incidence of various types of blood disorders. Thus, there is an increasing demand for early diagnosis and treatment of blood disorders. To enhance the quality of life of people suffering from hemorrhagic disease, key players are taking several initiatives through various organic and inorganic strategies. In October 2021, Trivitron Healthcare, a medical devices company, launched a new line of coagulation analyzer products manufactured by Diagon Ltd in India. In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110 that monitor diabetes, thalassemia, and hemoglobin variations. In February 2021, Siemens Healthineers and Sysmex Corporation renewed their long-standing agreement for the global supply, distribution, sales, and service of hemostasis products, which included an extension for multiple years. Further, Siemens Healthineers will distribute Sysmex's automated blood coagulation analyzers, including the CN-3000 and CN-6000, as part of their agreement. Laboratories are provided with these machines, the next generation of fully automated coagulation testing solutions. In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. In addition to the blood coagulation and platelet aggregation parameters, it also measures thrombosis and hemostasis parameters. In February 2018, Horiba, a Japanese manufacturer of precision instruments for measurement and analysis, launched the Yumizen G, a range of semiautomatic to fully automatic hemostasis solutions for clinical testing. In May 2018, Beckman Coulter company launched the DxH 900 hematology analyzer, which performs complete blood count and differential white blood cell tests with minimal repeats for use in mid-to high-volume clinical laboratories.

Thus, the key market players are adopting various organic and inorganic strategies, which are anticipated to provide additional opportunities for the growth of the Asia Pacific coagulation analyzers market during the forecast period.

Asia Pacific Coagulation Analyzers Market Overview

The Asia Pacific is the fastest-growing market for coagulation analyzers in a global scenario. The region is analyzed based on China, India, Japan, Australia, South Korea, and the Rest of the Asia Pacific. The factors that are likely to contribute to the market growth include significantly rising geriatric population, increasing incidences cardiovascular diseases, growing prevalence of bleeding disorder, development of distribution network, and increasing the development of coagulation analyzers.

Increasing prevalence of cardiovascular diseases in the region is the key factor driving the growth of the market. According to an article by the National Center for Biotechnology Information (NCBI) titled Cardiovascular Health and Diseases in China, Cardiovascular Disease (CVD) accounted for approximately 47% and 44% of all deaths in rural and urban areas, respectively, in 2019. Two out of every five deaths occur due to CVD, and it is predicted that over 330 million patients suffer from CVD in China. The patients suffering from stroke, heart failure, coronary heart disease, pulmonary heart disease, rheumatic heart disease, atrial fibrillation, lower extremity artery disease, congenital heart disease, and hypertension were found to be 13 million, 11 million, 9 million, 5 million, 4.87 million, 2.50 million, 2 million, 45.30 million, and 245.00 million, respectively.

Further, the increasing geriatric population is fueling the growth of the coagulation analyzers market due to the increasing demand for vascular disease diagnosis and treatment. According to European Parliament, Japan has the world's highest average age (48 years) and is the world's most aging country. According to the Japanese government statistics released in September 2020, more than one in four people in Japan are 65 years or older. Furthermore, according to World Bank data, Japan's population over 65 years was 36.07 million in 2021, a significant increase from 29.60 million in 2011. This makes Japan an overwhelmingly large country comprising a growing geriatric population. ~80,000 people are recorded to be over 100 years old in Japan; this number is expected to increase to 440,000 by 2050. Thus, the rising vascular diseases and the increasing geriatric population across the country will likely offer vital growth opportunities for the coagulation analyzers market in the coming years. Additionally, the rising geriatric population in India will increase the demand for coagulation analyzers as the old age group is highly prone to various vascular diseases. According to the Indian Ministry of Statistics and Program Implementation (MoSPI), India's elderly population is estimated to grow from 138 million in 2021 to 194 million by 2031, a 41% increase over a decade. The increasing geriatric population will increase the demand for various diagnostics and treatments related to vascular disease. Thus, the factors such as rising cardiovascular diseases, the implementation of national strategies, and the rising geriatric population will boost the growth of the coagulation analyzers market in India.

Asia Pacific Coagulation Analyzers Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Coagulation Analyzers Market Segmentation

The Asia Pacific coagulation analyzers market is segmented into product, test, technology, end users, and country.

Based on product, the Asia Pacific coagulation analyzers market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. The clinical laboratory analyzers segment held the larger Asia Pacific coagulation analyzers market share in 2022.

Based on test, the Asia Pacific coagulation analyzers market is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimer testing, platelet function tests, anti-factor xa tests, heparin and protamine dose response tests for act, and others. The prothrombin time testing segment held the largest Asia Pacific coagulation analyzers market share in 2022.

Based on technology, the Asia Pacific coagulation analyzers market is segmented into optical technology, mechanical technology, electrochemical technology, and other technologies . The optical technology segment held the largest Asia Pacific coagulation analyzers market share in 2022.

Based on end users, the Asia Pacific coagulation analyzers market is segmented into hospitals, clinical laboratories, point-of-care testing, and others . The clinical laboratories segment held the largest Asia Pacific coagulation analyzers market share in 2022.

Based on country, the Asia Pacific coagulation analyzers market is segmented into China, India, Japan, Australia, South Korea, and the Rest of the Asia Pacific. The China dominated the Asia Pacific coagulation analyzers market share in 2022.

Abbott Laboratories; Danaher Corp; F. Hoffmann-La Roche Ltd; Horiba Ltd.; Maccura Biotechnology Co Ltd; Nihon Kohden Corp; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Sysmex Corporation; and Thermo Fisher Scientific Inc., are among the leading companies operating in the Asia Pacific coagulation analyzers market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific coagulation analyzers market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific coagulation analyzers market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution